Advanced Immuno-Oncology Therapies Will Reshape Future Cancer Care

Published
08 Apr 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$11.50
62.9% undervalued intrinsic discount
08 Aug
US$4.27
Loading
1Y
-16.8%
7D
-20.9%

Author's Valuation

US$11.5

62.9% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 208%

Shared on24 Apr 25
Fair value Decreased 40%

AnalystConsensusTarget has decreased revenue growth from 0.7% to -1.4%, decreased discount rate from 10.2% to 9.2% and increased shares outstanding growth rate from 0.1% to 0.2%.

Shared on17 Apr 25
Fair value Decreased 11%

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 14.3x to 15.9x.